Video Experimental Relacionado
Updated: Aug 10, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoproteínas plasmáticas elevadas y enfermedad coronaria en hombres de 55 años o menos. Un estudio prospectivo es un
A G Bostom1, L A Cupples, J L Jenner
1Framingham Study, Epidemiology and Biometry Program, Framingham, Mass., USA.
JAMA
|August 21, 1996
Resumen
El aumento de la lipoproteína [Lp] es un factor de riesgo independiente significativo para la enfermedad coronaria prematura (CHD) en los hombres. Este hallazgo es comparable a los niveles altos de colesterol o bajos de HDL, destacando Lp (a) como un indicador clave de riesgo cardiovascular.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Lipidología Lipidología.
- Cardiología Preventiva Cardiología preventiva.
Sus antecedentes:
- La lipoproteína a) [Lp a) ] es una partícula de lipoproteína que se ha asociado con el riesgo cardiovascular.
- Investigaciones anteriores han sugerido un vínculo potencial entre los niveles elevados de Lp (a) y la enfermedad coronaria (CHD).
- Comprender el riesgo independiente conferido por Lp (a) es crucial para refinar las estrategias de evaluación del riesgo cardiovascular.
Objetivo del estudio:
- Determinar si la lipoproteína elevada (Lp) es un factor de riesgo independiente para la enfermedad coronaria prematura (CHD) en los hombres.
- Para comparar el riesgo asociado con Lp elevado (a) con otros factores de riesgo de ECC establecidos.
Principales métodos:
- Se realizó un estudio prospectivo utilizando la cohorte de descendencia de Framingham.
- 2191 hombres de entre 20 y 54 años, libres de enfermedad cardiovascular al inicio del estudio (1971-1975), fueron seguidos.
- Los eventos de incidentes de ECC se rastrearon hasta los 55 años de edad, con modelos de riesgos proporcionales utilizados para la estimación del riesgo.
Principales resultados:
- Después de un seguimiento mediano de 15,4 años, se produjeron 129 eventos de ECC.
- Los niveles elevados de Lp (a) mostraron un riesgo relativo (RR) de 1.9 (95% IC, 1.2-2.9) para la enfermedad coronaria prematura.
- La RR para la Lp{a} elevada fue comparable con el colesterol total alto (RR 1.8) y el HDL bajo (RR 1.8).
Conclusiones:
- La elevación de la Lp (a) plasmática se confirma como un factor de riesgo independiente para la ECC prematura en los hombres.
- La magnitud y la prevalencia del riesgo de niveles elevados de Lp (a) son comparables a los niveles altos de colesterol total o bajos de HDL.
- Lp (a) debe considerarse un factor significativo para evaluar el riesgo de un individuo de desarrollar una enfermedad cardiovascular prematura.
Videos de Conceptos Relacionados
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...